Exclusive-Lilly halts India obesity awareness campaign after regulatory scrutiny, seeks rules clarity

Lilly’s campaign aimed to reframe obesity as a chronic disease. The regulator cited concerns about indirect promotion of Lilly’s drug Mounjaro. This has created regulatory uncertainty for the company and the industry.Read More